3.895
2.50%
-0.105
Eledon Pharmaceuticals Inc stock is traded at $3.895, with a volume of 199.18K.
It is down -2.50% in the last 24 hours and up +31.31% over the past month.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
See More
Previous Close:
$4.00
Open:
$3.92
24h Volume:
199.18K
Relative Volume:
0.58
Market Cap:
$236.66M
Revenue:
-
Net Income/Loss:
$-40.33M
P/E Ratio:
-0.6524
EPS:
-5.97
Net Cash Flow:
$-39.53M
1W Performance:
-21.37%
1M Performance:
+31.31%
6M Performance:
+29.14%
1Y Performance:
+207.09%
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Name
Eledon Pharmaceuticals Inc
Sector
Industry
Phone
949-238-8090
Address
19800 MACARTHUR BLVD., IRVINE
Compare ELDN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ELDN | 3.90 | 236.66M | 0 | -40.33M | -39.53M | -5.97 |
VRTX | 467.79 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 761.02 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 564.78 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 230.27 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.65 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-13-22 | Resumed | Cantor Fitzgerald | Overweight |
Mar-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
Research Analysts Set Expectations for ELDN FY2024 Earnings - MarketBeat
FY2024 Earnings Forecast for ELDN Issued By Lifesci Capital - MarketBeat
ARMISTICE CAPITAL, LLC Acquires Shares in Eledon Pharmaceuticals Inc - GuruFocus.com
Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutions - Yahoo Finance
Institutions along with individual investors who hold considerable shares inEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) come under pressure; lose 16% of holdings value - Simply Wall St
Hopkins alum leads Eledon Pharmaceuticals in breakthrough diabetes tegoprubart treatment - Johns Hopkins News-Letter
Eledon Pharmaceuticals Reports Strong Q3 2024 Results - TipRanks
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results - The Manila Times
Eledon Pharma Surges: $85M Offering, Strong Trial Results Drive Q3 Success | ELDN Stock | ELDN Stock News - StockTitan
Amyotrophic Lateral Sclerosis Treatment Market to Grow by USD 663.7 Million from 2024-2028, as Rising Incidence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
Midday Stock Roundup: Indie Semiconductor Up 43% - Orange County Business Journal
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference - The Manila Times
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation - The Bakersfield Californian
Eledon Pharmaceuticals CEO to Present at Guggenheim's First Healthcare Innovation Conference | ELDN Stock News - StockTitan
RA Capital Management, L.P. Acquires New Stake in Eledon Pharmac - GuruFocus.com
Biotechnology Value Fund L P's Strategic Acquisition in Eledon P - GuruFocus.com
ELDN stock touches 52-week high at $4.13 amid robust gains - Investing.com Australia
ELDN stock touches 52-week high at $4.13 amid robust gains By Investing.com - Investing.com South Africa
SEC Form 424B5 filed by Eledon Pharmaceuticals Inc. - Quantisnow
Eledon drug helps transplants 'cure' type 1 diabetes - pharmaphorum
Eledon Pharmaceuticals sets terms for $85 million stock offering By Investing.com - Investing.com South Africa
Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart (ELDN) - Seeking Alpha
Eledon Pharmaceuticals Shares Hit 52-Week High After Positive Trial Data - MarketWatch
Promising results for diabetes treatment with new drug By Investing.com - Investing.com Australia
Eledon Pharmaceuticals sets terms for $85 million stock offering - Investing.com India
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine - The Manila Times
Promising results for diabetes treatment with new drug - Investing.com India
Eledon Pharmaceuticals Announces Pricing of $85 Million - GlobeNewswire
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - StockTitan
Algorae Pharmaceuticals Plans Major Securities Issuance - MSN
ELDN stock soars to 52-week high, touches $3.35 amid surge - Investing.com
Financial Analysis: Eledon Pharmaceuticals (NASDAQ:ELDN) & ABVC BioPharma (NASDAQ:ABVC) - Defense World
IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, - openPR
IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, Pipeline, Medication, Therapies, Treatment Market and Companies by DelveInsight - Barchart
Eledon Pharmaceuticals completes $4 million equity sale - Investing.com India
Eledon Pharmaceuticals completes $4 million equity sale By Investing.com - Investing.com South Africa
Nantahala Capital Management LLC Invests $1.58 Million in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Nantahala Capital Management LLC Acquires New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - MarketBeat
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Update - MarketBeat
Midday Stock Roundup: STAAR Surgical CO. Shares Surge 22% - Orange County Business Journal
Eledon Pharmaceuticals initiates $75 million stock sale agreement By Investing.com - Investing.com Australia
Eledon Pharmaceuticals initiates $75 million stock sale agreement - Investing.com
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference - GlobeNewswire
ELDNEledon Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Eledon Announces Completion of Enrollment in Phase 2 BESTOW - GlobeNewswire
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients - StockTitan
Short Interest in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Declines By 6.8% - MarketBeat
Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):